BeiGene, Ltd.

ONC · Moat type: REGULIERUNG

MoatScore

4/10

Fair Value

69 USD

Margin of Safety

-360.3 %

Rating

BEOBACHTEN

BeiGene is a globally positioned oncology biotechnology company that generates revenues through the development, manufacturing, and commercialization of proprietary cancer medications — including notably the BTK inhibitor Zanubrutinib — revenues increasingly supported by a growing portfolio of in-house developed and licensed active pharmaceutical ingredients.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.